{"id":"W2286152207","doi":"10.1200/jco.2015.33.7_suppl.141","title":"Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Prostate cancer; Docetaxel; Brief Pain Inventory; Randomization; Mitoxantrone; Internal medicine; Population; Enzalutamide; Cabazitaxel; Cabozantinib; Oncology; Cancer; Randomized controlled trial; Urology; Androgen deprivation therapy; Chemotherapy; Chronic pain; Physical therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001864375,0.0002812113,0.002551231,0.000387037,0.00003966058,0.00001988992,0.00008902753,0.0001497464,0.00006583874],"category_scores_gemma":[0.0004681846,0.0001676596,0.0001304448,0.0006503721,0.0002532119,0.0001747061,0.00003439693,0.0004416961,6.091958e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002559726,"about_ca_system_score_gemma":0.001833456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009010533,"about_ca_topic_score_gemma":0.01493825,"domain_scores_codex":[0.9963111,0.0007662759,0.001807472,0.0003550349,0.0004104401,0.0003496611],"domain_scores_gemma":[0.9958315,0.001287161,0.001444628,0.0001551588,0.0007065142,0.0005750647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.34434,0.003293685,0.6108156,0.0001390256,0.006758687,0.0009631431,0.001418455,0.002775552,0.0002895773,0.000007278575,0.0006297426,0.02856929],"study_design_scores_gemma":[0.1512846,0.1351019,0.6902743,0.0005486959,0.01579529,0.0001310618,0.000940042,0.003275941,0.0002486914,0.00001576703,0.00200152,0.0003821953],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962498,0.000892875,0.00003965815,0.001753755,0.0001183377,0.0007713788,0.00009293404,0.000006501171,0.0000747438],"genre_scores_gemma":[0.9954915,0.0009926835,0.002525513,0.0004921291,0.00008344754,0.00004070916,0.00002595105,0.00002341535,0.000324628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1930553,"threshold_uncertainty_score":0.8335892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1474909085450899,"score_gpt":0.4478939216211045,"score_spread":0.3004030130760146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}